Genmab stock holds after recent earnings and pipeline updates
Published on 07/22/2026 at 03:24 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Genmab (DK0010272202) continues to trade with the market focused on its latest reported financials, pipeline execution, and valuation context. The company reported revenue of DKK 12.5 billion for 2025, up from DKK 11.4 billion in 2024, while operating profit reached DKK 3.4 billion in 2025 compared with DKK 2.7 billion a year earlier.
Revenue and profit mix
The 2025 figures show a business that kept growing while expanding profit. Revenue rose by DKK 1.1 billion year on year, and operating profit increased by DKK 0.7 billion over the same period, giving investors a clear comparison between top-line and earnings progress.
Genmab also said it ended 2025 with strong cash generation, including free cash flow of DKK 4.1 billion, versus DKK 3.5 billion in 2024. That matters because cash flow gives the company more room to fund antibody programs without depending only on fresh capital.
Cash flow at DKK 4.1 billion
The margin profile also improved across the period. With revenue at DKK 12.5 billion and operating profit at DKK 3.4 billion in 2025, the operating margin came to about 27%, compared with roughly 24% in 2024, based on the same reported figures.
That change is small in percentage terms but meaningful in absolute kroner, because it shows Genmab converting more of its revenue base into earnings. For a biotech group with a concentrated product portfolio, that is the metric that tends to matter most.
Pipeline still drives valuation
Genmab’s valuation remains tied to its antibody pipeline and partnered products, which the company continues to highlight in its investor relations materials. In that setup, the market usually pays close attention to each program update, because revenue quality and future growth depend on how reliably the pipeline can replace older revenue streams.
The company’s latest annual reporting also points to a business that is still scaling beyond a single product cycle. That is important for the stock because the market typically rewards biopharma names when reported cash flow, revenue growth, and pipeline depth all move in the same direction.
Darzalex remains key
A central product reference for Genmab is Darzalex, the multiple myeloma therapy partnered with Johnson & Johnson. It remains the most visible commercial driver associated with Genmab’s antibody platform and continues to shape how investors read the company’s reported numbers.
For the stock, the key question is how long that contribution can support growth while newer assets move forward. The 2025 revenue and profit figures suggest that the current model still works, but the next set of updates will matter for judging the pace of transition.
Stock level focus
Genmab shares were last described in the market around their broader 2025 reporting backdrop, with the stock context tied to the company’s DKK 12.5 billion revenue base and DKK 3.4 billion operating profit. Those figures frame the discussion until the next dated market quote or fresh company update becomes available.
Genmab at a glance
- Company: Genmab A/S
- ISIN: DK0010272202
- Ticker: CPSE: GMAB
- Trading venue: Nasdaq Copenhagen
- Sector / Industry: Health Care / Biotechnology
- Index membership: OMX Copenhagen 25
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
